Price$6.83+0.03 (+0.44%)
01:30 PM07:45 PM
News · 26 weeks41+29%
2026-03-012026-08-23
Mix1690d
- SEC Filings8(50%)
- Other5(31%)
- Earnings2(13%)
- Analyst1(6%)
Latest news
25 items- SECProfound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRProfound’s Introduction of New Real-time Interventional MRI Software Paving the Way for Full ‘TULSA Days’TORONTO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI ("iMRI") procedures, today announced the introduction of its latest Treatment Delivery Consol ("TDC") software. The new TDC software, which is being deployed across Profound’s TULSA-PRO® installed base, further builds upon previously implemented TULSA-AI® modules focused on increasing procedural efficiency and physician experience, while reducing planning complexity. It brings two new focuses of features that are designed to even further increase TULSA Procedure™ efficiency
- SECProfound Medical Corp. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRProfound Medical Announces Management ChangeTORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced the promotion of Matthew Sobczyk from Corporate Controller to Interim Chief Financial Officer, effective immediately. Mr. Sobczyk, who first joined Profound in 2020, succeeds Rashed Dewan, who has stepped down as the Company’s Chief Financial Officer. "I would like to thank Rashed for his years of service and the contributions he has made to the Company, and I am pleased that he will be staying on a short-term consulting contract to help en
- SECProfound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRProfound Medical Launches ‘Let's Huddle’, a Global Community Supporting Men Throughout Their Prostate Care JourneyTORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI ("iMRI") procedures, today announced the launch of Let's Huddle, a global patient community designed to empower men and their families with education, connection, and support throughout every stage of the prostate care journey. The new patient advocacy initiative, led by Leonard Wheeler, Profound’s Global Patient Ambassador, former NFL player, prostate cancer survivor, and men's health advocate, brings together patients, survivors, care partners, healthcare professionals, an
- SECSEC Form 10-Q filed by Profound Medical Corp.10-Q - Profound Medical Corp. (0001628808) (Filer)
- SECProfound Medical Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRProfound Medical Reports Second Quarter 2026 Financial Results– Operating expenses decline 16%, helping drive a 39% improvement in net loss – – Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing – – Strong clinical, commercial and reimbursement momentum continues – – Company reiterates full-year 2026 revenue guidance – – Announces first employer owned health plans to list the TULSA Procedure™ as a covered service – TORONTO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI ("iMRI") procedures, today announced financial results for the second
- ANALYSTProfound Medical upgraded by Raymond James with a new price targetRaymond James upgraded Profound Medical from Outperform to Strong Buy and set a new price target of $11.00
- SECProfound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRRobotic Radical Prostatectomy Comes Up ‘Short’ in CAPTAIN TrialTORONTO, July 24, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced new data from the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure™ with robotic radical prostatectomy ("robotic RP") in men with organ-confined, intermediate-risk, Gleason Score 7 (Grade Group 2 and 3) prostate cancer. At 1 month following the TULSA Procedure, there was no median change in penile length, compared with a median 0.65 cm reduction in penile length after robotic RP. The new penile length re
- SECProfound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRProfound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to FollowTORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, will announce its second quarter 2026 financial results after market close on Thursday, August 6, 2026. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Second Quarter 2026 Results Conference Call Details: Date: Thursday, August 6, 2026 Time: 4:30 p.m. ET Live Call Registration: https://register-conf.media-server.com/register/BI1680e67d2b6f4f81b268df3183400d
- SECProfound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRProfound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026TORONTO, July 15, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") is pleased to announce that its MRI-guided, AI-powered, Robotically-Driven and Incisionless TULSA Procedure™ will be highlighted in several presentations by leading physicians at the upcoming Society of Robotic Surgery ("SRS") Annual Meeting to be held in Fort Lauderdale, FL, July 23-26, 2026.* MAIN CONGRESS SESSIONS Real-world Outcomes after MRI-guided Transurethral Ultrasound Ablation of the Prostate in a Multicenter Post-market Registry Xiaosong Meng, MD, PhD; UT Southwestern Medical Center, Dallas, TXJuly 24, 2026; 9:55:10:00 a.m. EDT CAPTAIN Randomized Contro
- SECSEC Form EFFECT filed by Profound Medical Corp.EFFECT - Profound Medical Corp. (0001628808) (Filer)
- SECProfound Medical Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRTelix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment ApproachesTelix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes. MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ:EDAP, "EDAP")) and Profound Medical Corp. (NASDAQ:PROF, TSX:PRN, "Profound")
- SECProfound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRProfound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI ("iMRI") procedures, is pleased to announce that the TULSA Procedure™ will be highlighted in four oral presentations at the upcoming American Urological Association's ("AUA") Annual Meeting in Washington, DC, in the session titled "Prostate Cancer: Localized: Ablative Therapy II" on May 16th from 1:00-3:00 p.m. ET. TULSA Procedure Talks at AUA2026 Ram A. Pathak, M.D., Associate Professor in the Department of Urology at Mayo Clinic in Florida, will give a presentation titled
- SECSEC Form S-3 filed by Profound Medical Corp.S-3 - Profound Medical Corp. (0001628808) (Filer)
- SECSEC Form 10-Q filed by Profound Medical Corp.10-Q - Profound Medical Corp. (0001628808) (Filer)
- SECProfound Medical Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRProfound Medical Reports Strong First Quarter 2026 Financial Results– Quarterly results marked by 104% revenue growth and improved operating performance – – Company issues full-year 2026 revenue guidance – – Announces Humana is now covering the TULSA Procedure™ – TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI ("iMRI") procedures, today reported financial results for the first quarter ended March 31, 2026. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAA
PROF FAQ
6 questionsWhat does Profound Medical Corp. do?
Profound Medical Corp., together with its subsidiaries, operates as a medical technology company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive...Where does PROF stock trade?
Profound Medical Corp. (PROF) is listed on NASDAQ.What sector and industry is PROF in?
Profound Medical Corp. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about PROF?
Profound Medical Corp. has had 8 recent analyst actions on file. The most recent action was from Raymond James: Strong Buy with a $1100.00 price target on 2026-07-27. Recent price targets range from $1000.00 to $2300.00.What companies are similar to PROF?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare PROF side-by-side with any of them on Quantisnow.How can I track PROF on Quantisnow?
Quantisnow aggregates Profound Medical Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PROF to receive live email and push alerts on every new disclosure.